Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks

SpringWorks Therapeutics

28/04/2025 07:07

FRANKFURT, April 28 (REUTERS) - German healthcare and materials group Merck KGaA MRCG.DE said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics SWTX.O for an equity value of $3.9 billion to boost its cancer drug business.

Darmstadt, Germany-based Merck said in a statement that the purchase price of $47 per share in cash represents an equity value of about $3.9 billion, equivalent to an enterprise value of $3.4 billion (3.0 billion euros), when SpringWorks’ cash holdings are deducted.

 (Reporting by Ludwig Burger; Editing by Kirsten Donovan)

 ((ludwig.burger@thomsonreuters.com;))